Limited evidence exists on the impact of hormone receptor (HR) status to counsel HER2-positive early breast cancer patients receiving adjuvant anti-HER2 therapy.
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
Lambertini, Matteo;
2019-01-01
Abstract
Limited evidence exists on the impact of hormone receptor (HR) status to counsel HER2-positive early breast cancer patients receiving adjuvant anti-HER2 therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lambertini M et al_Breast Cancer Res Treat 2019.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
1.56 MB
Formato
Adobe PDF
|
1.56 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
